Macular degeneration needs longer lasting treatmentsBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7524 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7524
- S James Talks, consultant ophthalmologist1
- 1Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK
Clinical trials show that bevacizumab can work as well as ranibizumab for the treatment of age related macular degeneration.1 For patients to gain the full visual benefit they need four weekly review and possible treatment. This has proved difficult for patients, relatives, and healthcare providers. Real world outcome data have failed to show the same visual …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial